Founded in July 2016 and headquartered in Brooklyn, New York, Concarlo is a precision-medicine oncology company focused on diagnosing and treating cancer with an innovative approach to targeting a unique cellular pathway - p27Kip1. Concarlo's novel IpY therapeutic will be the first inhibitor to solve the CDK2 resistance issue, the first therapeutic to target p27 and the first to inhibit CDK4 and CDK2 simulataneously.
Creative Destruction Lab
Creative Destruction Lab (CDL) is a nonprofit organization that delivers an objectives-based program for massively scalable, seed-stage, science- and technology-based companies
Accelerator
